Classes
DEA Class; Rx
Common Brand Names; Ortho Est, Ogen 5, Ogen 2.5, Ogen 1.25, Ogen 0.625
- Estrogen Derivatives
Description
An oral synthetic estrogen that is piperazine-stabilized estrone sulfate (1.2 mg of estropipate is equivalent to 1 mg of sodium estrone sulfate)
Used primarily for hormone replacement to treat vasomotor and genitourinary symptoms of menopause
Also used for prevention of osteoporosis and for treating estrogen deficiency
Indications
Indicated for treatment of moderate to severe vasomotor symptoms (hot flashes) of menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae), whether menopause is natural or surgical (e.g., due to oophorectomy).
Contraindications
Documented hypersensitivity
Active or history of breast cancer
Arterial thromboembolic disease (stroke, MI), thrombophlebitis, DVT/PE, thrombogenic valvular disease
Estrogen-dependent neoplasia, liver disease, liver tumors
Undiagnosed abnormal vaginal bleeding
Uncontrolled hypertension
Diabetes mellitus with vascular involvement
Jaundice with prior oral contraceptive use
Adverse Effects
- Peripheral edema
- Depression
- Headache
- Melasma
- Bloating
- Nausea & vomiting
- Breast enlargement & tenderness
- Amenorrhea
- Breakthrough bleeding
- Spotting
- Weight changes
- Corneal curvation change
Warnings
Diabetes mellitus, endometriosis, hyperlipidemias, HTN, hypothyroidism, elderly, hepatic/renal impairment, uterine leiomyomata, porphyria, patients with defects of lipoprotein metabolism, hypertriglyceridemia, ovarian cancer, exacerbation of endometriosis or other conditions, smoking and >35 years old, SLE, depression
Fluid retention may exacerbate asthma, epilepsy, migraines, & cardiac or renal dysfunction
Discontinue if the following develop jaundice, visual problems (may cause contact lens intolerance), any signs of VTE, migraine with unusual severity, significang blood pressure increase, severe depression, increased risk of thromboembolic complications after surgery.
Hypercalcemia may occur in patients with breast cancer and bone metastases
Increased risk of endometrial and ovarian cancer in postmenopausal women
Long-term postmenopausal estrogen treatment has been associated with increased risk of breast cancer, MI, stroke, DVT, PE, and dementia
May increase risk of thromboembolic disorders, may need to increase anticoagulant dose when administering concomitantly with anticoagulants
Pregnancy and Lactation
Pregnancy Category: X
Lactation: Controversial; estrogens are excreted into breast milk in small quantities, use caution
Maximum Dosage
9 mg/day PO.
6 mg/day PO for menopausal indications.
9 mg/day PO.
Use not indicated in prepubescent females.
How supplied
Estropipate
tablet
- 0.75mg
- 1.5mg
- 3mg
- 6mg